antibodies -online.com





anti-SIGLEC7 antibody (N-Term)

3 Images



Go to Product page

()	1 /	\sim	KI /	110	Νę
	1//	\vdash	I \/	1 ←	٠// ٢

Overview		
Quantity:	400 μL	
Target:	SIGLEC7	
Binding Specificity:	AA 1-30, N-Term	
Reactivity:	Human	
Host:	Rabbit	
Clonality:	Polyclonal	
Conjugate:	This SIGLEC7 antibody is un-conjugated	
Application:	Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))	
Product Details		
Immunogen:	This SIGLEC7 (D-siglec) antibody is generated from rabbits immunized with a KLH conjugated	
	synthetic peptide between 1-30 amino acids from the N-terminal region of human SIGLEC7 (D-	
	siglec).	
Clone:	RB2711	
Isotype:	Ig Fraction	
Purification:	This antibody is purified through a protein A column, followed by peptide affinity purification.	
Target Details		
Target:	SIGLEC7	
Alternative Name:	SIGLEC7 (D-siglec) (SIGLEC7 Products)	

Target Details

Background:

SIGLECs are cell surface proteins of the Ig superfamily. Most SIGLECs have 1 or more cytoplasmic immune receptor tyrosine-based inhibitory motifs, or ITIMs. A large subgroup of SIGLECs share high homology with SIGLEC3 (CD33) and are localized to 19q13.4. The cDNA for the SLG gene encodes 2 variants, SLG-long (SLGL) and SLG-short (SLGS). The 595-amino acid SLGL protein contains a signal peptide and 2 V-set N-terminal Ig-like domains. The 477-amino acid SLGS protein has a weak signal sequence and, like most SIGLEC3-like SIGLECs, has only 1 V-set N-terminal Ig-like domain. Both variants contain 2 C2-set N-terminal Ig-like domains, a transmembrane domain, and a cytoplasmic tail with a putative ITIM and a putative SLAM-like tyrosine-based motif. The conserved arginine residue thought to be essential for sialic acid binding in other SIGLECs is replaced by a glutamine in SLGS and by a cysteine in SLGL. RT-PCR analysis detected high expression of both variants in spleen and small intestine, and SLGS was highly expressed in adrenal gland and SLGL was highly expressed in bone marrow.


Molecular Weight:	51143
Gene ID:	27036
NCBI Accession:	NP_001264130, NP_055200, NP_057627
UniProt:	Q9Y286


Application Details


Application Notes:	WB: 1:2000. WB: 1:1000. IHC-P: 1:50~100
Restrictions:	For Research Use only

Handling

Format:	Liquid	
Buffer:	Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.	
Preservative:	Sodium azide	
Precaution of Use:	This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.	
Storage:	4 °C,-20 °C	
Storage Comment:	Maintain refrigerated at 2-8 °C for up to 6 months. For long term storage store at -20 °C in small aliquots to prevent freeze-thaw cycles.	
Expiry Date:	6 months	







Immunohistochemistry (Paraffin-embedded Sections)

Image 1. Formalin-fixed and paraffin-embedded human cancer tissue reacted with the primary antibody, which was peroxidase-conjugated to the secondary antibody, followed by DAB staining. This data demonstrates the use of this antibody for immunohistochemistry, clinical relevance has not been evaluated. BC = breast carcinoma, HC = hepatocarcinoma.

Western Blotting

Image 2. All lanes: Anti-Dsiglec-W20 at 1:2000 dilution Lane 1: A549 whole cell lysate Lane 2: NCI- whole cell lysate Lane 3: Human liver lysate Lysates/proteins at 20 µg per lane. Secondary Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/10000 dilution. Predicted band size: 51 kDa Blocking/Dilution buffer: 5 % NFDM/TBST.

Western Blotting

Image 3. Western blot analysis of anti-SIGLEC7 Pab (ABIN388428 and ABIN2837865) in NCI- cell line lysate (35 μ g/lane). SIGLEC7(arrow) was detected using the purified Pab.